Clinical Trial
Immunological intervention in endotoxin shock
Affiliations
- PMID: 3293079
Item in Clipboard
Clinical Trial
Immunological intervention in endotoxin shock
Prog Clin Biol Res.
1988.
No abstract available
Similar articles
-
Monoclonal antibodies and the treatment of gram-negative bacteremia and shock.N Engl J Med. 1991 Feb 14;324(7):486-8. doi: 10.1056/NEJM199102143240709. N Engl J Med. 1991. PMID: 1988835 No abstract available.
-
Lipopolysaccharide (LPS) from the cellular wall of Gram-negative bacteria, also known as endotoxin, is a key molecule in the pathogenesis of sepsis and septic shock. Preface.Blood Purif. 2014;37 Suppl 1:1. doi: 10.1159/000357412. Epub 2014 Jan 20. Blood Purif. 2014. PMID: 24457486 No abstract available.
-
Clinical studies of monoclonal anti-lipid A antibody XMMEN-0E5.Prog Clin Biol Res. 1988;272:395-406. Prog Clin Biol Res. 1988. PMID: 3293083 Clinical Trial. No abstract available.
-
The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.Infect Dis Clin North Am. 1991 Dec;5(4):899-913. Infect Dis Clin North Am. 1991. PMID: 1783775 Review.
-
Antiendotoxin therapies for septic shock.Infect Agents Dis. 1993 Feb;2(1):44-52. Infect Agents Dis. 1993. PMID: 8162353 Review.
Cited by
-
The Autodigestion Hypothesis in Shock and Multi-Organ Failure: Degrading Protease Activity.Bol Soc Port Hemorreol Microcirc. 2011 Jul;26(3):6-15. Bol Soc Port Hemorreol Microcirc. 2011. PMID: 25284955 Free PMC article.